O. G. Zonenko

O. G. Zonenko

Auto-generated profile, based on publicly available information

O. G. Zonenko

Federal State Autonomous Educational Institution of Higher Education “N.I.Pirogov Russian National Research Medical University” of the Ministry of Health of the Russian Federation

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2018 in Journal of Clinical Practice
Verified
Journal Article
Open access
PDF file
SKS. A. Krasovskiy
S. A. Krasovskiy
EAElena Amelina
Elena Amelina
UGU. V. Gorinova
U. V. Gorinova
ACA. V. Chernyak
A. V. Chernyak
MAM. V. Afanasjeva
M. V. Afanasjeva
КАКрылова Наталья Анатольевна
Крылова Наталья Анатольевна
Background: Evaluation of the main clinical and functional indicators and their relationship with the treatment and diagnostic care at different time periods can contribute to the development of further effective medical strategies and globally lead to improved care for cystic fibrosis patients. Aim: An assessment of the dynamics of some clinical and functional indicators in adult CF patients, who have been observed ed Research Institute of Pulmonology during the last 15 years(2003–2018). Methods: The comparative analysis was performed on the data of adult patients with cystic fibrosis, observed at 31.12.2003 and at the end of October of 2018. The group of patients in 2003 consists of 80 and in 2018 — of 667 patients. The comparative analysis between the groups was carried out according to the following indicators: age, survival, lung function, nutritional status, proportion of infection with pathogenic microflora, identification of mutations in the cystic fibrosis gene and diagnosis in adult patients. Results: An increase in patient’s age, survival rate, the proportion of identified mutations in cystic fibrosis gene and infection of Burkholderia cepacia complex in the group of patients in 2018 was revealed. There were no differences in the state of lung function, nutritional status, the ratio of the living and dead patients and proportion of patients diagnosed in adulthood between groups. Conclusion: The progress in the treatment through the introduction of modern methods and therapeutic programs leads to improved survival and an increase in the number of adult patients with cystic fibrosis.

22 April 2019 in Siberian Medical Review
Verified
Journal Article
Closed access
PIPulmonology Scientific Research Institute
Pulmonology Scientific Research Institute
SKS.A. Krasovskiy
S.A. Krasovskiy
MAM.V. Afanasjeva
M.V. Afanasjeva
EAElena Amelina
Elena Amelina
АCАlexander Cherniak
Аlexander Cherniak
DHD. D.Pletnev City Clinical Hospital
D. D.Pletnev City Clinical Hospital

13 April 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
SKS. A. Krasovskiy
S. A. Krasovskiy
RKR. U. Kagazezhev
R. U. Kagazezhev
OZO. G. Zonenko
O. G. Zonenko
DSD. F. Sergienko
D. F. Sergienko
NBN. S. Butyugina
N. S. Butyugina
MGMikhail Yurevich Gushchin
Mikhail Yurevich Gushchin
Introduction. Cystic fibrosis is a severe systemic multiorgan exocrinopathy, the severity of the condition in 95% cases is caused by the depth of respiratory organ damage. Symptom management drugs that were developed over more than 50 years allowed to improve survival, but average life expectancy in cystic fibrosis (CF) remains well below the general population average. Targeted therapy is the most promising treatment, which restores the chloride channel function. Lumacaftor/ivacaftor is the first targeted therapy drug authorized in Russia.Aim. To evaluate the effect of lumacaftor/ivacaftor therapy on the respiratory function, microbiological profile, nutritional and oxygen status, as well as the rescue antibiotic therapy coverage in adult patients with CF.Materials and methods. 39 adult patients with CF received lumacaftor/ivacaftor for one year. The therapy effectiveness endpoints included the changes in indices of the pulmonary function tests: FEV1, FVC, FEV1/FVC, sweat test results, nutritional and oxygen status, antibiotic therapy coverage. The tolerability of the drug was assessed. The median age of patients was 28.9 (11.3) years. 6 patients (15.4%) discontinued therapy due to different adverse reactions.Results. The median increase in FVC was 2.9 (4.1)%, in FEV1 – 3.1 (4.1)%, sweat chloride decreased by 21 (27) mmol/l during 1–1.5-month lumacaftor/ivacaftor therapy. After 12-month therapy, the median increase in FVC was 2.3 (3.6)%, in FEV1 – 2.4 (3.8)%, BMI increased by 0.6 (0.6) kg/m2 and the frequency of rescue antibiotic therapy decreased by half. The patients showed a significant increase in FVC and FEV1 indices and a decrease in sweat chloride after 1-month therapy and an increase in FEV1 indices, BMI vales as well as a reduced need for rescue antibiotic therapy after 12-month therapy.Conclusion. The first experience with a long-term pathogenetic therapy with lumacaftor/ivacaftor in adult patients with CF in Russia demonstrated the expected positive effect on the respiratory function and changes in nutritional status, a reduced need for rescue antibiotic therapy, and low rates of adverse reactions.

22 April 2019 in Siberian Medical Review
Verified
Journal Article
Closed access
SKS.A. Krasovskiy
S.A. Krasovskiy
PIPulmonology Scientific Research Institute
Pulmonology Scientific Research Institute
EAElena Amelina
Elena Amelina
NKNataliya Kashirskaya
Nataliya Kashirskaya
AVAnna Voronkova
Anna Voronkova
PUPirogov Russian National Medical Research Medical University
Pirogov Russian National Medical Research Medical University

1 January 2024 in Voprosy detskoj dietologii
Verified
Journal Article
Closed access
OZO.G. Zonenko
O.G. Zonenko
ORO.V. Ryazanova
O.V. Ryazanova
SSS.YU. Semykin
S.YU. Semykin
PSP.V. Shumilov
P.V. Shumilov
This article reviews the characteristics of one of the most serious complications of cystic fibrosis (CF), cystic fibrosis-related diabetes (CFRD). In recent years, there has been an increase in the incidence of CFRD, which increases the risk of adverse clinical outcomes in CF. At the same time, the early clinical manifestations of CFRD are ambiguous, diagnosis is difficult, and some issues of pathogenesis remain unexplored. The presented four clinical cases of CFRD in pairs of sibs from three families with severe CF and pancreatic insufficiency demonstrates the necessity of monitoring carbohydrate metabolism indicators for early detection of possible disorders and their timely pharmacological correction, as well as the importance of closer attention of physicians to this problem. Key words: cystic fibrosis, cystic fibrosis-related diabetes, children, treatment

1 June 2019 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
EKE. Kondratyeva
E. Kondratyeva
EFE. Furman
E. Furman
VSV. Shadrina
V. Shadrina
ACA. Chernyak
A. Chernyak
EAEvgeniya Amelina
Evgeniya Amelina
VYV. Yakovleva
V. Yakovleva